东诚药业 ：下属公司获药物临床试验批准通知书

Core Viewpoint - Dongcheng Pharmaceutical (002675) announced that its subsidiary LNC PHARMA PTE.LTD. received FDA approval for the clinical trial of 225Ac-LNC1011 injection, which will soon commence Phase I clinical trials for treating advanced prostate cancer patients with PSMA-positive expression [1] Company Summary - Dongcheng Pharmaceutical's subsidiary, LNC PHARMA PTE.LTD., has been granted FDA approval for a clinical trial [1] - The drug 225Ac-LNC1011 is intended for the treatment of advanced prostate cancer patients [1] Industry Summary - The approval of 225Ac-LNC1011 marks a significant step in the development of targeted therapies for prostate cancer [1] - The focus on PSMA-positive expression in advanced prostate cancer highlights the industry's trend towards precision medicine [1]